{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,20]],"date-time":"2026-11-20T12:15:30Z","timestamp":1795176930015,"version":"4.10.3"},"reference-count":26,"publisher":"Informa UK Limited","issue":"24","license":[{"start":{"date-parts":[[2022,7,11]],"date-time":"2022-07-11T00:00:00Z","timestamp":1657497600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100001003","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001003","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Future Oncol."],"published-print":{"date-parts":[[2022,8]]},"DOI":"10.2217\/fon-2022-0196","type":"journal-article","created":{"date-parts":[[2022,7,11]],"date-time":"2022-07-11T09:44:52Z","timestamp":1657532692000},"page":"2639-2649","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":66,"title":["Phase I trial of the DLL3\/CD3 bispecific T-cell engager BI 764532 in DLL3-positive small-cell lung cancer and neuroendocrine carcinomas"],"prefix":"10.1080","volume":"18","author":[{"given":"Martin","family":"Wermke","sequence":"first","affiliation":[{"name":"Technical University Dresden,Medical Faculty,NCT\/UCC Early Clinical Trial Unit,\rDresden,\rGermany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enriqueta","family":"Felip","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology,Vall d\u2019Hebron University Hospital &amp; Vall d\u2019Hebron Institute of Oncology,\rBarcelona,\rSpain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Gambardella","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology,Hospital Cl\u00ednico Universitario,INCLIVA Biomedical Research Institute,University of Valencia,\rValencia,\rSpain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasutoshi","family":"Kuboki","sequence":"additional","affiliation":[{"name":"Department of Experimental Therapeutics,National Cancer Center Hospital East,\rKashiwa,\rChiba,\rJapan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Morgensztern","sequence":"additional","affiliation":[{"name":"Washington University School of Medicine,\rSt. Louis,\rMO 63110,\rUSA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zohra Oum\u2019","family":"Hamed","sequence":"additional","affiliation":[{"name":"Boehringer Ingelheim France S.A.S.,\rReims,\rFrance"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meiruo","family":"Liu","sequence":"additional","affiliation":[{"name":"Boehringer Ingelheim Pharmaceuticals Inc,\rRidgefield,\rCT 06877,\rUSA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matus","family":"Studeny","sequence":"additional","affiliation":[{"name":"Boehringer Ingelheim International GmbH,\rIngelheim,\rGermany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taofeek K","family":"Owonikoko","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology,UPMC Hillman Cancer Center,University of Pittsburgh,\rPA 15232,\rUSA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2022,7,11]]},"reference":[{"key":"e_1_3_5_3_1","unstructured":"American Cancer Society . Cancer facts and figures 2021. Atlanta: American Cancer Society (2021). www.cancer.org\/research\/cancer-facts-statistics\/all-cancer-facts-figures\/cancer-facts-figures-2021.html (Accessed 13September2021)."},{"key":"e_1_3_5_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2016.01.012"},{"key":"e_1_3_5_5_1","doi-asserted-by":"publisher","DOI":"10.2147\/CMAR.S174907"},{"key":"e_1_3_5_6_1","doi-asserted-by":"publisher","DOI":"10.2147\/OTT.S204577"},{"key":"e_1_3_5_7_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-0926"},{"key":"e_1_3_5_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30565-4"},{"key":"e_1_3_5_9_1","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aac9459"},{"key":"e_1_3_5_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2017.11.018"},{"key":"e_1_3_5_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2019.10.010"},{"key":"e_1_3_5_12_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.729765"},{"key":"e_1_3_5_13_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12022-020-09657-8"},{"key":"e_1_3_5_14_1","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aav0891"},{"key":"e_1_3_5_15_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-019-0745-2"},{"key":"e_1_3_5_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2021.02.009"},{"key":"e_1_3_5_17_1","first-page":"A656","article-title":"AMG 757, a half-life extended bispecific T-cell engager (BiTE) immune therapy against DLL3 in SCLC: Phase I interim results","volume":"8","author":"Borghaei H","year":"2020","unstructured":"Borghaei H , BoyerM, JohnsonMet al. AMG 757, a half-life extended bispecific T-cell engager (BiTE) immune therapy against DLL3 in SCLC: Phase I interim results. J. Immunother. Cancer8, A656\u2013A959 (2020).","journal-title":"J. Immunother. Cancer"},{"issue":"15","key":"e_1_3_5_18_1","first-page":"Abstract TPS908","article-title":"Phase I study of AMG 757, a half-life extended bispecific T-cell engager (HLE BiTE immune therapy) targeting DLL3, in patients with small cell lung cancer (SCLC)","volume":"38","author":"Owonikoko TK","year":"2020","unstructured":"Owonikoko TK , BorghaeiH, ChampiatSet al. Phase I study of AMG 757, a half-life extended bispecific T-cell engager (HLE BiTE immune therapy) targeting DLL3, in patients with small cell lung cancer (SCLC). J. Clin. Oncol.38(Suppl. 15), Abstract TPS9080 (2020).","journal-title":"J. Clin. Oncol."},{"key":"e_1_3_5_19_1","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.TARG-19-C033"},{"key":"e_1_3_5_20_1","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0258(19980530)17:10<1103::AID-SIM793>3.0.CO;2-9"},{"key":"e_1_3_5_21_1","doi-asserted-by":"publisher","DOI":"10.1002\/sim.3230"},{"key":"e_1_3_5_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30565-4"},{"key":"e_1_3_5_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2021.03.012"},{"key":"e_1_3_5_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2021.07.012"},{"key":"e_1_3_5_25_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2021.39.15_suppl.8510"},{"issue":"16","key":"e_1_3_5_26_1","first-page":"Abstract TPS860","article-title":"Trial-in-progress: phase 2 study of tarlatamab, a DLL3-targeting half-life extended bispecific T-cell engager (HLE BiTE\u00ae) immuno-oncology therapy, in relapsed\/refractory small cell lung cancer (SCLC)","volume":"40","author":"Ramalingam SS","year":"2022","unstructured":"Ramalingam SS , AhnM-J, AkamatsuHet al. Trial-in-progress: phase 2 study of tarlatamab, a DLL3-targeting half-life extended bispecific T-cell engager (HLE BiTE\u00ae) immuno-oncology therapy, in relapsed\/refractory small cell lung cancer (SCLC). J. Clin. Oncol.40(Suppl. 16), Abstract TPS8603 (2022).","journal-title":"J. Clin. Oncol."},{"key":"e_1_3_5_27_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2022.40.6_suppl.TPS197"},{"issue":"16","key":"e_1_3_5_28_1","article-title":"Interim results of an ongoing Phase I\/IIa study of HPN328, a tri-specific, half-life extended, DLL3-targeting, T-cell engager, in patients with small cell lung cancer and other neuroendocrine cancers","volume":"40","author":"Johnson M","year":"2022","unstructured":"Johnson M , DyG, MamdaniHet al. Interim results of an ongoing Phase I\/IIa study of HPN328, a tri-specific, half-life extended, DLL3-targeting, T-cell engager, in patients with small cell lung cancer and other neuroendocrine cancers. J. Clin. Oncol.40(Suppl. 16), Abstract 8566 (2022).","journal-title":"J. Clin. Oncol."}],"container-title":["Future Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.2217\/fon-2022-0196","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,23]],"date-time":"2024-06-23T06:43:42Z","timestamp":1719125022000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.2217\/fon-2022-0196"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,11]]},"references-count":26,"journal-issue":{"issue":"24","published-print":{"date-parts":[[2022,8]]}},"alternative-id":["10.2217\/fon-2022-0196"],"URL":"https:\/\/doi.org\/10.2217\/fon-2022-0196","relation":{},"ISSN":["1479-6694","1744-8301"],"issn-type":[{"value":"1479-6694","type":"print"},{"value":"1744-8301","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,11]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifon20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifon20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2022-02-23","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-06-24","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-07-11","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}